Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Rhea-AI Summary

Dynavax Technologies (NASDAQ:DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after U.S. market close.

The company will host a conference call and audio webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Participants are advised to join approximately 10 minutes before the call starts. The webcast will be accessible through the company's investor relations website, with a replay available for 30 days.

Dynavax currently markets two commercial products: HEPLISAV-B vaccine for hepatitis B prevention and CpG 1018 adjuvant, which is used in multiple COVID-19 vaccines.

News Market Reaction

-0.18%

1 alert

-0.18% News Effect

On the day this news was published, DVAX declined 0.18%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

EMERYVILLE, Calif., July 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2025 financial results on Thursday, August 7, 2025, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B^® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018^® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.

For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499 

Nicole Arndt
narndt@dynavax.com
510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-second-quarter-2025-financial-results-and-host-conference-call-on-august-7-2025-302516281.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax (DVAX) report Q2 2025 earnings?

Dynavax will report Q2 2025 financial results on Thursday, August 7, 2025, after the U.S. financial markets close.

What time is the Dynavax (DVAX) Q2 2025 earnings call?

The earnings conference call and webcast will take place on Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT.

How can I access Dynavax's (DVAX) Q2 2025 earnings webcast?

The webcast can be accessed through the 'Events & Presentations' page in the 'Investors' section of Dynavax's website at investors.dynavax.com. A replay will be available for 30 days.

What are Dynavax's (DVAX) main commercial products?

Dynavax has two main commercial products: HEPLISAV-B vaccine for hepatitis B prevention and CpG 1018 adjuvant, which is used in various COVID-19 vaccines.